

INDEX

A

- Absolute claudication distance, initial claudication distance *v*, s132
- Acetylsalicylic acid, s248
- Activated partial thromboplastin time, s65
- Activated protein C, resistance to, assay for, s65
- Acute limb ischemia
- anatomic improvement in, s147
 - anticoagulant therapy in, s150
 - catheter-directed thrombolysis *v* surgical revascularization in, s155
 - classification system for, s144
 - clinical categories of, s143
 - clinical classification of, s142
 - clinical outcomes in, s146
 - clinical presentation of, s135-136
 - clinical trial issues in, s164
 - combining treatments within trial groups in, s166
 - conditions mimicking, s138
 - definition of, s135
 - diagnosis of, urgency of, s144
 - differential diagnosis of, s137, 138
 - economic aspects of, s163-164
 - effectiveness assessment in, s147
 - endovascular procedures for, s151-152
 - etiology of, s135
 - factors for intervention selection in, s151
 - follow-up care in, s160-161
 - functional status in, s148
 - health-related quality of life in, s148
 - hemodynamic improvement in, s147
 - imaging in, s141
 - immediate management of, s150
 - management algorithm for, s161-163
 - motor function loss in, s137
 - outcome assessment methodology in, s145-146
 - patient history in, s136
 - perioperative angiography in, s155
 - physical examination in, s136-137
 - predicting outcome in, s143-144
 - procedural morbidity in, s147-148
 - procedural mortality in, s147-148
 - sensory function loss in, s137
 - severity levels in, s142-144
 - subcutaneous heparin in, s151
 - surgery in, s154-158
 - surgical technique in, s154-155
 - symptom recurrence in, s148
 - technical therapy success in, s146-147
 - therapeutic options in, s158
 - therapy of, s150
 - therapy success reportage in, s149
 - thrombolysis following arteriography in, s152
 - treating underlying lesion in, s159-160
 - treatment crossovers in, s166
 - trial cost-effectiveness analysis in, s167
 - trial end point selection in, s166-167
 - trial entry criteria in, s164
 - trial failures in, s165
 - trial intention-to-treat rule in, s164-165
 - trial standardizing reporting practices in, s165-166
 - trial stratification treatment groups in, s165
- Age
- critical limb ischemia and, s22
 - intermittent claudication and, s9, s10
- Ambulation, s264
- Aminophylline, s93
- Amputation
- as clinical trial end point, s284
 - cost of, s278-279
 - incidence of, s21-22, s24-25
 - indications for, s267
 - level of, s26
 - numbers of, s26
 - primary, s267-268
 - risk factors for, s25-26
 - secondary, s268
 - selection of, s268-269
 - technical principles of, s270
- Amputee, fate of, s26-27
- Anesthesia, s237
- Aneurysm, thrombosed popliteal, management of, s161
- Angiogenesis, gene-induced therapeutic, in critical limb ischemia, s200-201
- Angiography, s256
- alternatives to, s72
 - in intermittent claudication, s71
 - perioperative, s155
- Ankle pressure, in critical limb ischemia, s178
- Ankle pressure measurement, s66-67
- Ankle pulse
- detection of, s6
 - intermittent claudication and, and ankle-brachial pressure index, s7
- Ankle-Brachial Pressure Index, s67, s254-255
- cardiovascular disease and, s15
 - claudication progression and, s17-18
 - in critical limb ischemia, s189
 - intermittent claudication and, and pulse, s7
 - measurement of, s7-8
- Antibiotics, s237
- in ulcer therapy, s195

Anticardiolipin antibody assay, s65
 Anticoagulant, s249
 in critical limb ischemia, s199
 Anticoagulation, long-term, following thromboembolism, s161
 Antiphospholipid antibodies, test for, s65
 Antiphospholipid syndrome, s64
 Antiplatelet therapy, s82, s92
 in critical limb ischemia, s199
 Antithrombin assay, s65
 Antithrombin deficiency, s64
 due to low-protein state, s64
 Aortobifemoral bypass, s205
 patency following, s114
 Aortoiliac disease
 endovascular treatment of, s214-215
 preferred therapeutic options for, s215
 surgical treatment of, s205
 Aortoiliac endarterectomy, s205-207
 Aortoiliac percutaneous transluminal balloon angioplasty, s98
 Aortoiliac reconstruction, s239
 Aortoiliac stent, s101
 indications for, s102
 Arterial dissection, s139
 Arterial thrombosis, due to hypercoagulable state, s139
 Arterial trauma, s139
 Arteriovenous fistula, s221
 Arteritis, s139
 Arthritis, of hip, differential diagnosis of, s59
 Atheroembolism, s138-139
 Atherosclerosis
 evaluation for, s65-66
 systemic, progression and, s18
 Axillobifemoral bypass, s115
 Axillofemoral bypass, s207-208
 Axillounifemoral bypass, s211

B

Bakers cyst, symptomatic, differential diagnosis of, s59
 Basle study, s16
 Beraprost, s90, s91
 Biochemical study, in intermittent claudication, s62-63
 Blood, ultraviolet irradiated autologous, s263
 Blood lipid study, in intermittent claudication, s63
 Buerger's disease, s58-59, s185, s187
 claudication due to, s59
 Buflomedil, s90, s91
 Buttock, differential diagnosis of, s59

C

Calf, intermittent claudication of, differential diagnosis of, s59
 Cancer-associated thrombosis, s64
 Capillary microscopy, in critical limb ischemia, s180

Cardiovascular disease
 ankle-brachial pressure index and, s15
 peripheral arterial disease and, s15
 Cardiovascular morbidity prevention trial, in intermittent claudication, s133-134
 Cardiovascular mortality prevention trial, in intermittent claudication, s133
 Carnitine, s93-94
 Catheter-directed thrombolysis, surgical revascularization », in acute limb ischemia, s155
 Causalgia, s184
 Cerebrovascular disease, peripheral arterial disease and, s14-15
 Chelation therapy, s265
 Chronic compartment syndrome, s57-58
 differential diagnosis of, s59
 Chronic critical limb ischemia
 definition problems in, s169-171
 historical background in, s168-169
 nomenclature in, s168
 proposed definition of, s170
 Chronic subcritical ischemia, s170-171
 Cigarette smoking, s80
 Cilostazol, s90, s91, s92
 Cinnarizine, s90
 Claudicant, s54
 coronary artery disease in, s20
 fate of, s20
 five-year fate of, s21
 Claudication, s54
 Claudicator, s54
 Clinical trial
 additional variables in, s286
 adjuvant pharmacotherapy in, s286-287
 constant » graded treadmill exercise protocol in, s131-132
 design of, in critical limb ischemia, s281-282
 end point selection in, s166-167
 end points for, s131, s133
 entry criteria in, s286
 inclusivity » exclusivity in, s129, s282-283
 operator variability in, s286
 outcome reporting timing in, s285
 patient stratification in, s283-284
 patients entered in, s287
 possible primary end points in, of critical limb ischemia, s284-285
 quality of life measurements in, s133
 secondary end points in, s132-133
 secondary interventions in, s287
 standardizing reporting practices in, s165-166
 statistical » clinical significance in, s132
 stratification in, s130-131
 stratification treatment groups in, s165
 treatment crossovers in, s166

Coarctation, claudication due to, s59
Color flow duplex scanning, s255-256
 in intermittent claudication, s71-72
Conduit, choice of, s218-219
Consensus process
 caveat for, s3-4
 essential criteria for, s1
 history of, s1, s2
 methodology of, s1, s4
 objectives of, s1
Coronary artery disease
 in claudicants, s20
 peripheral arterial disease and, s14-15
Coronary Artery Surgery Study, s19
Cost(s)
 of critical limb ischemia therapy, s275, s276, s277-280
 of diagnostic procedures, s275
 fixed, s48
 health care, s46-47
 intangible, s47-48
 opportunity, s47
 semi-fixed, s48
 tangible non-health care, s47
 variable, s48
Cost data
 collection of, s46
 computation of, s46-47
Cost minimization analysis, s48
Cost-benefit analysis, s48-49
Cost-effectiveness, in intermittent claudication
 of antiplatelet therapy, s124-125
 of lipid control, s125-126
Cost-effectiveness analysis, s48
Cost-utility analysis, s48
Coumarin, s249
 in acute limb ischemia, s160
Cramps, night, s185
Critical limb ischemia
 age and, s22
 ankle pressure in, s178
 basic treatment of, s193-194
 cardiovascular events in, s287
 changing outcome of, s23-24
 clinical definition of, s170
 clinical trial issues in, s281-288
 contralateral leg in, s287
 current criteria for, high-risk patients not covered by, s171
 definition of, s21
 diabetes and, s23
 diagnostic evaluation in, objectives for, s182
 differential diagnosis of, s184-185
 economic aspects of, s274
 effectiveness measures in, s190

 foot care in, s194
 history of, s176
 imaging in, s180-181
 incidence of, s21-22
 interventional options in, risks of, s181-182
 interventional treatment of, s204
 investigations for, s178
 life-threatening coexisting disease therapy in, s194
 management algorithm for, s274
 management plan in, s173-175
 microcirculatory investigations in, s179
 microcirculatory pathophysiology in, s171-173
 multidisciplinary team approach in, s173-174
 outcome assessment methodology in, s188-190
 patient audits in, s175
 patient fate in, s23, s24, s25
 patient management costs in, s279-280
 pharmacotherapy for, s197-201
 physical examination in, s176-177
 prevalence of, s21-22
 prognosis in, s171
 progression of, s282
 reporting standards definition of, s170
 risk factor control in, s195-196
 risk factors for, s22-23
 risks odds ratio in, for mortality, s22
 secondary interventions in, s287
 smoking and, s22
 sympathectomy, s265
 testing for, s178, s180, s182
 toe pressure in, s178-179
 treatment of, s192-193
 trial secondary end points in, s286
Crossover bypass graft, long-term results of, s211
Cyclosporin, s251
Cyst, popliteal, s139

D

Decision modeling, in peripheral arterial disease therapy, s51-52
Defibrinogenating agent, in critical limb ischemia, s200
Defibrotide, s93
Descriptive instrument, s37
Dextran, s249, s90
Diabetes mellitus, s237-238
 claudication progression and, s17
 critical limb ischemia and, s196, s23
 foot in, s173
 intermittent claudication and, s56-57
 neuropathic ulcer of, s186
 peripheral arterial disease and, s11, s80
Diabetic neuropathy, s184
Diabetic patient, evaluating, considerations in, s68
Diagnosis-Related Group, reimbursement schedule for, s48

Dilute Russell Viper Venom Test, s64, 65
 Doppler arterial studies, s141
 Doppler pressure measurement, s269
 Doppler velocity wave form analysis, s68-69
 Duplex scanning, s141
 Dysfibrinogenemia, s64

E

Economic evaluation
 limitations of, s49-51
 of peripheral arterial disease therapy, s45-51
 principles of, s45-46
 Edinburgh questionnaire, diagnostic performance of, s5-6
 Effectiveness, efficacy *v*, s49
 Embolus(i)
 in acute limb ischemia, s135-136
 atherosclerotic plaque disruption cholesterol, s138-139
 peripheral, claudication due to, s59-60
 Endovascular procedure
 in acute limb ischemia, s155-158
 complications of, s109-111
 Epidural spinal cord stimulation, s264
 Ergotism, s139
 Erythrocyte sedimentation rate, in intermittent claudication, s63
 Euglobulin lysis time, s65
 EuroQol, s42
 Exercise
 rehabilitation with, s83-85
 unsupervised, s118
 External iliac dysplasia, claudication due to, s59-60

F

Factor V Leiden, assay for, s65
 Factor V Leiden mutation, s64
 Factor XII deficiency, s64
 Fasciotomy, in acute limb ischemia, s159
 Femorofemoral bypass, s210-211
 Femoropopliteal angioplasty, s227-231
 Femoropopliteal bypass
 above-knee, vein *v* prosthetic grafts for, s116
 conduit for, s116
 Femoropopliteal bypass graft, s222-223
 Femoropopliteal lesion
 interventional treatment of, s106
 morphological stratification of, s104-105
 Femoropopliteal percutaneous transluminal balloon angioplasty, s103
 Femoropopliteal stent, s106, s109
 patency of, s107-108
 Fibrinogen, peripheral arterial disease and, s12
 Fixed cost, s48
 Fontaine stage, of peripheral arterial disease, s39
 Foot

 in diabetes, s173
 intermittent claudication of, s59
 ulcer of, s185
 Framingham study, s16
 Functional status
 in acute limb ischemia, s148
 improvement in, s190
 Functional status assessment, s39-40
 in intermittent claudication, s69-70

G

Gamble, standard, s41-42
 Graft
 failed, s238
 proximal, s275
 Graft surveillance, appropriate use of, s256-258

H

Health Utility Index, s42
 Hematologic study, in intermittent claudication, s62-63
 Hemodilution, in critical limb ischemia, s200
 Heparin, s249
 subcutaneous, in acute limb ischemia, s151
 Heparin-induced thrombocytopenia, s64
 Herniated disc, differential diagnosis of, s59
 Hexopal, s90
 Hip
 arthritis of, s59
 osteoarthritis of, s58
 Homocysteine, in peripheral arterial disease, s82
 Hormone replacement therapy, s82
 Hyperbaric oxygen, s263-264
 Hypercoagulability, peripheral arterial disease and, s12
 Hypercoagulable state
 intermittent claudication and, s56-57
 in peripheral arterial disease, s82
 types of, s64
 Hyperhomocysteinemia, s64
 peripheral arterial disease and, s12
 Hyperlipidemia
 in critical limb ischemia, s196
 intermittent claudication and, s56-57
 peripheral arterial disease and, s12, s81
 Hypertension
 claudication progression and, s18
 in critical limb ischemia, s195
 intermittent claudication and, s56-57
 in peripheral arterial disease, s81
 peripheral arterial disease and, s12
 Hypoplastic aorta, s209

I

Iliac artery occlusion, s100

- Iliac artery stenosis, endovascular therapy of, patency rates for, s100
- Iliac lesion
- interventional management of, s99
 - morphological stratification of, s98
- Iliac to femoral bypass, s210
- Imaging, in intermittent claudication, s70-72
- Impaired glucose tolerance, peripheral arterial disease and, s11
- Infrainguinal bypass graft, s222-226
- Infrainguinal disease, s233-236, s209-210
- surgical therapy of, s217
- Infrainguinal vein bypass grafting, s241
- Infrapopliteal percutaneous transluminal balloon angioplasty, s108-109
- Initial claudication distance, absolute claudication distance v, s132
- Insulin resistance, peripheral arterial disease and, s11
- Intangible cost, s47-48
- Intention-to-treat rule, s164-165
- Intermittent claudicant, definition of, s170
- Intermittent claudication
- absolute v initial claudication distance in, s132
 - by age group, s9, 10
 - ankle-brachial pressure index and, s7
 - antiplatelet therapy in, cost-effectiveness of, s124-125
 - asymptomatic, prevalence of, s10
 - background treatment of, s129-130
 - cardiovascular morbidity prevention trials in, s133-134
 - cardiovascular mortality prevention trials in, s133
 - clinical assessment of, s6, s56-62
 - clinical measures in, s75
 - clinical trial guidelines for, s127
 - clinical trial objectives in, s127
 - clinical trial reporting standards for, s127
 - clinical v quality-of-life outcomes in, s74-75
 - constant v graded treadmill exercise protocol in, s131-132
 - death in, causes of, s19-20
 - defining, problem with, s5
 - definition of, s54
 - diagnostic strategies for, s122-123
 - differential diagnosis of, s57, s59
 - economic aspects of, s122
 - endovascular procedures for, s97-111
 - genetic risk for, s13
 - grading pulses in, s61
 - hemodynamic abnormalities in, s54-55
 - history in, s56-57
 - imaging techniques in, s70-72
 - incidence of, s8
 - invasive therapy in, indications for, s79
 - lipid control in, cost-effectiveness of, s125-126
 - management algorithm for, s86
 - medical treatment of, s122
 - in men, s11
 - mortality of, s18-19
 - natural history of, s129
 - nomenclature for, s54
 - nonfatal cardiovascular events in, s18
 - overall strategy in, s77-78
 - patient characteristics in, s54
 - patient-based outcomes parameters in, s75-76
 - pharmacotherapy for, s89-95
 - physical examination for, s60-61
 - prevalence of, s8-10
 - progression from, to peripheral arterial disease, s79
 - progression of, s15, s17
 - protective factors for, s13
 - quality of life measurements in, s133
 - risk factor odds ratios for, s14
 - risk factors for, s10, s13, s56-57
 - routine tests for, s62-67
 - smoking and, s13
 - statistical v clinical significance in, s132
 - surgery for, s113-120
 - therapeutic options for, s117-120
 - treatment algorithm for, s121
 - treatment costs for, s123-124
 - trial end points in, s133
 - trial secondary end points in, s132-133
 - walking test in, s130
 - worsening of, s15-16
- Intimal hyperplasia, agents to inhibit, s250-251
- Intramuscular gene transfer, in critical limb ischemia, s201
- Isovolemic hemodilution, s92-93
- J**
- Juxtarenal aortic occlusion, s208
- K**
- Ketanserin, s251, s92
- L**
- L-arginine, s251, s95
- Laser Doppler fluxmetry, in critical limb ischemia, s179
- Leg, ulcer of, differential diagnosis of, s185
- Limb salvage, following chronic critical limb ischemia therapy, s189
- Lipid study, blood, in intermittent claudication, s63
- Lumbar spine, osteoarthritis of, s58
- Lumbar sympathectomy, s116
- Lupus anticoagulant, s65
- M**
- Magnetic resonance angiography, s141
- in intermittent claudication, s72
- Malnutrition, s64

McMaster Health Index Questionnaire, s118
 Medical Outcome Study Short-Form 36, s40
 Meta-analysis, in peripheral arterial disease therapy, s51-52
 Metabolic syndrome, peripheral arterial disease and, s11

N

Naftidrofuryl, s90, 91
 Naroparcil, s251
 Negative pressure application, s264
 Nephrotic syndrome, s64
 Nerve root compression, s184
 differential diagnosis of, s59
 Neuroischemic ulcer, s186
 Neuropathic ulcer, s186
 Neurospinal, s54
 Night cramp, s185
 Nitric oxide, s172, s250

O

Obesity, s80
 Occlusive arterial lesion, causes of, s59
 Opportunity cost, s47
 Osteoarthritis
 of hip, s58
 of lumbar spine, s58
 Outcome measure(s)
 objective, s38
 symptomatic, s38-39, s75-76
 Outcomes, efficacy measures for, s35-36
 Outcomes research, in peripheral arterial disease, s35-36
 Oxygen, hyperbaric, s263-264

P

Pain, control of, in critical limb ischemia, s193-194
 Patency
 assisted primary, s37
 definition of, s43
 determination of, s42-43
 primary, s37
 Pentoxifylline, s89-91
 Perceived health, s40
 Percutaneous aspiration thrombectomy, s153
 Percutaneous mechanical thrombectomy, s153
 Percutaneous transluminal balloon angioplasty, s97
 aortoiliac, s98
 surgery v, s119
 Peripheral arterial claudication, coexisting risk factors for, s13
 Peripheral arterial disease
 catheter intervention in, s97
 classification of, s39
 claudication due to, s59
 coexisting vascular diseases and, s13-15
 diabetes and, s11

 efficacy measures in, s35
 epidemiology of, s5
 fibrinogen and, s12
 hemodynamic abnormalities in, s54-55
 hypercoagulability and, s12
 hyperhomocysteinemia and, s12
 hyperlipidemia and, s12
 hypertension and, s12
 metabolic abnormalities of, s55
 neurological abnormalities of, s55
 outcomes research in, s35
 risk factors for, s13, s14
 smoking and, s11-12
 Peripheral arterial disease therapy
 decision modeling in, s51-52
 economic aspects of, s45-51
 economic evaluation limitations in, s49-51
 meta-analysis in, s51-52
 procedural complications of, s36
 success criteria for, s36-38
 technical success of, s36
 Peripheral nerve pain, s58
 Peripheral sensory neuropathy, s184
 Persistent sciatic arteries, claudication due to, s59-60
 Plasma fibrinogen level, s65
 Plasminogen
 abnormal, s64
 deficiency of, s64
 level of, s65
 Plasminogen activator deficiency, s64
 Platelet aggregation test, s65
 Platelet count, s65
 Platelet reactivity, abnormal, s64
 Popliteal aneurysm, thrombosed, management of, s161
 Popliteal artery aneurysm, thrombosed, s139
 Popliteal artery segment, isolated, s218
 Popliteal cyst, s139
 claudication due to, s59-60
 Popliteal entrapment, s139
 claudication due to, s59-60
 Procedural mortality, definition of, s190
 Propionyl-L-carnitine, s90, s91
 Prostacyclin, s172
 Prostaglandin, s94
 Prostanoid, s94, s250
 clinical trial of, s198
 in critical limb ischemia, s197, s199
 Prosthetic graft, surveillance of, s256-258
 Protein C assay, s65
 Protein C deficiency, s64
 Protein S assay, s65
 Protein S deficiency, s64
 Protein-losing enteropathy, s64

Prothrombin mutation, s64
Prothrombin time, s65
Proximal revascularization, s216-217
Pseudoxantoma elasticum, claudication due to, s59-60
Psychological well-being, s40
Pulses
 absent, s6
 in acute limb ischemia, s137
 grading, for intermittent claudication, s61
 intermittent claudication and, s7
 peripheral, detection of, s6
Pulse volume recording, s68

Q

Quality-adjusted life year, s41
Quality of life
 assessment of, s40-41
 in critical limb ischemia, s285
 improvement in, s190
 in intermittent claudication, s76
 valuing health-related, s41-42
Quality of Well-Being Scale, s42
Questionnaire
 disease-specific health status, s30
 Edinburgh, s5-6
 generic health status, s39-40
 for intermittent claudication detection, s5
 WHO-Rose, s5

R

Radionuclide perfusion scan, in critical limb ischemia, s179
RAND-36, s40-41
Reflex sympathetic dystrophy, s184
Reperfusion injury, s159
Revascularization, surveillance following, s253-258
Role function evaluation, s40
Rutherford category, of peripheral arterial disease, s39

S

Segmental limb systolic pressure measurement, s67-68
Segmental plethysmography, s68
Semi-fixed cost, s48
Sensory neuropathy, diabetic, s184
Short Form 36, s40-41, s76
Short-term morbidity, definition of, s190
Skin perfusion pressure management, s270
Smoking
 cessation of, in critical limb ischemia, s195
 claudication progression and, s17
 critical limb ischemia and, s22
 intermittent claudication and, s13
 peripheral arterial disease and, s11-12
Spinal cord compression, s58

 differential diagnosis of, s59
Spinal cord stimulation, epidural, s264
Spiral computed tomography, in intermittent claudication, s72
Standard gamble, s41-42
Stent, s245
 multiple, cost-effectiveness of, s102
 proximal, s275
STILE trial, s156
 major findings of, s157
Stress test, alternative, s70
Summary receiver operating characteristic curve, s51
Surgical revascularization, catheter-directed thrombolysis *v*, in
 acute limb ischemia, s155
Sympathectomy
 in acute limb ischemia, s151
 in critical limb ischemia, s265
 lumbar, indications for, s266

T

Thigh, differential diagnosis of, s59
Thoracofemoral bypass, s208
Thrombin time, s65
Thromboangitis obliterans, *see* Buerger's disease
Thrombolysis
 in acute limb ischemia, s151-152
 contraindications to, s152-153
 high-dose systemic, in arterial occlusion, s152
Thrombophilia, s63
Thrombosis
 in acute limb ischemia, s135-136
 arterial, due to hypercoagulable state, s139
 associated with inflammatory bowel disease, s64
 graft, s160
Ticlopidine, s90, s91, s248
Time trade-off, s41-42
Tobacco abuse, intermittent claudication and, s56-57
Toe pressure, in critical limb ischemia, s178-179
TOPAS trial, s156-157
Transcutaneous oxygen measurement, s269-270
 in critical limb ischemia, s179
Trousseau's thrombosis, s64

U

Ulcer(s)
 associated with hematologic disease, s187
 diabetic neuropathic, s186
 etiological classification of, s185
 foot, differential diagnosis of, s185
 healing of, s284
 leg, s185
 systemic therapy of, s195
 topical therapy of, s194
 treatment of, s194-195

venous, s185-186
Ultraviolet irradiated autologous blood, s263

V

Valuational instrument, s37
Valuational measure, s37
Variable cost, s48
Vascular endothelial growth factor, s94
 in critical limb ischemia, s201
Vascular registry
 advantages of, s261-262
 problems with, s261
Vasculitis, s186-187
Vasoactive drug(s)
 in acute limb ischemia, s151
 in critical limb ischemia, s200

Vasodilator, s91
Vein bypass graft, surveillance of, s256-258
Venous claudication, s57
 differential diagnosis of, s59
Venous compression, intermittent, s264
Venous cuff, s221
Venous ulcer, s185-186
Verapamil, s90, s92
Vitamin E, s93

W

Walking, s264
Walking distance, s75
Walking test, in intermittent claudication, s130
WHO-Rose questionnaire, diagnostic performance of, s5